The study aimed to synthesize dexibuprofen (DXIBN) solid dispersions (SDS)-loaded hydroxypropylmethylcellulose (HPMC) and co-acrylic acid (AA)-based oral hydrogels via a modest solvent evaporation technique. Free radical polymerization technique was used to prepare HPMC-co-AA hydrogels using EGDMA as cross-linker and ammonium per sulfate as initiator. SDS of DXIBN were prepared using Soluplus® (SLPS^®) as a solubilizing agent. The solubility of pure DXIBN and the respective SDS was analyzed in phosphate buffer solutions (PBS) at varying pH (1.2, 6.8 and 7.4 pH) at temperatures (25 and 37 °C). The physiochemical characterizations: swelling analysis, diffusion co-efficient, porosity and sol-gel analysis, Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC), swelling behavior and release studies (at pH 1.2 and 7.4) were steered. The solubility was found to be significantly (p < .05) improved up to twofolds as compared to pure DXIBN. The hydrogels with higher concentrations of HPMC and AA showed significant (p < .05) increase in swelling, whereas there was a significant (p < .05) decrease with higher concentration of cross-linker EGDMA. The release kinetics applied trailed overall the non-Fickian release mechanism. The existing work exhibited was found to be improved DXIBN solubility using Soluplus via SDS technique and a stable HPMC-co-AA DXIBN release retardant hydrogel as an exceptional safer tool for the treatment of rheumatoid arthritis.

该研究旨在通过适度的溶剂蒸发技术合成负载去氧布洛芬（DXIBN）固体分散体（SDS）和羟丙基甲基纤维素（HPMC）和基于共丙烯酸（AA）的口服水凝胶。采用自由基聚合技术，以EGDMA为交联剂，过硫酸铵为引发剂，制备HPMC-co-AA水凝胶。使用Soluplus®（SLPS制备DXIBN的SDS ^®）作为增溶剂。在温度（25和37°C）下，在变化的pH（1.2、6.8和7.4 pH）下，在磷酸盐缓冲溶液（PBS）中分析纯DXIBN和相应SDS的溶解度。进行了理化表征：溶胀分析，扩散系数，孔隙率和溶胶-凝胶分析，傅立叶变换红外光谱（FTIR）和差示扫描量热法（DSC），溶胀行为和释放研究（在pH 1.2和7.4时）。发现 与纯DXIBN相比，溶解度显着提高（p <.05）高达两倍。含有较高浓度HPMC和AA的水凝胶的 肿胀显着（p <.05）增加，而存在显着（p <.05）随交联剂EGDMA浓度的升高而降低。应用的释放动力学落后于整个非菲克式的释放机理。发现通过SDS技术使用Soluplus可以提高DXIBN的溶解度，并且稳定的HPMC-co-AA DXIBN释放延迟水凝胶可作为类风湿性关节炎的更安全工具，从而提高了DXIBN的溶解度。